Using in vitro and in vivo studies, they demonstrated that high levels of IRAK1 in HCC enhance the expression of AKR1B10, a downstream effector of AP-1 and a main regulator of tumor-initiating cells (TICs), thereby promoting doxorubicin or sorafenib resistance. The gene discussed is IRAK1; the disease is hepatocellular carcinoma.